INS and type 1 diabetes mellitus: Although not approved for use in T1DM because of concerns over the potential risk of diabetic ketoacidosis, recent evidence from clinical trials suggests that low-dose empagliflozin, when used in conjunction with insulin therapy, might improve glycemic control and metabolic parameters in individuals with T1DM [7,8].